JP Morgan Initiates Esperion Therapeutics With Overweight

Analysts at JP Morgan initiated coverage on Esperion Therapeutics Inc ESPR with a Overweight rating. The target price for Esperion Therapeutics is set to $130. Esperion Therapeutics shares have gained 454.22 percent over the past 52 weeks, while the S&P 500 index has surged 7.73 percent in the same period. Esperion Therapeutics' shares jumped 0.08 percent to $84.09 in after-hours trading.